Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KLK1 | P06870 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5320853 | 0.90 | F10 (0.65) | F10KLK1F2KCNH2 | |
| SCHEMBL5324672 | 0.88 | F10 (0.64) | F10KLK1F2KCNH2 | |
| SCHEMBL5324898 | 0.88 | F10 (0.66) | F10KLK1KCNH2 | |
| Hydrochloric Acid SCHEMBL5322543 | 0.87 | F10 (0.63) | F10KLK1F2KCNH2 | |
| SCHEMBL5329273 | 0.82 | F10 (0.57) | F10KLK1KCNH2 | |
| SCHEMBL5326100 | 0.81 | F10 (0.58) | F10KLK1KCNH2 | |
| SCHEMBL5328255 | 0.81 | F10 (0.69) | F10KLK1F2KCNH2 | |
| SCHEMBL5321809 | 0.80 | F10 (0.68) | F10KLK1F2KCNH2 | |
| SCHEMBL5706940 | 0.77 | F10 (0.54) | F10KLK1 | |
| SCHEMBL5327935 | 0.74 | F10 (0.71) | F10F2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419979-B2 | Derivatives of 6-{4-[4-(1H-indole-2-sulphonyl)-piperazin-1-carbonyl-phenyl]}pyradizin-3-one | ASTRAZENECA AB (SE) | 2008-09-02 | — | — | US | claimed |
| JP-2007517870-A | — | — | 2007-07-05 | — | — | JP | claimed |
| US-20070135441-A1 | New derivatives of 6-{4-[4-(1h-indole-2-sulphonyl)-piperazin-1-carbonyl-phenyl]}pyradizin-3-one | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | claimed |
| WO-2007008144-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | claimed |
| EP-1706120-A1 | NEW DERIVATIVES OF 6- 4 4 - 1 H - INDOLE-2-SULPHONYL)-PIPERA ZIN-1-CARBONYL-PHENYL PYRADIZIN-3-ONE | AstraZeneca AB (SE) | 2006-10-04 | — | — | EP | claimed |
| WO-2005065688-A1 | NEW DERIVATIVES OF 6-4{4-[1H-INDOLE-2-SULPHONYL)-PIPERAZIN-1-CARBONYL-PHENYL]}PYRADIZIN-3-ONE | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | WO | claimed |
| US-7419979-B2 | Derivatives of 6-{4-[4-(1H-indole-2-sulphonyl)-piperazin-1-carbonyl-phenyl]}pyradizin-3-one | ASTRAZENECA AB (SE) | 2008-09-02 | — | — | US | disclosed |
| US-20070135441-A1 | New derivatives of 6-{4-[4-(1h-indole-2-sulphonyl)-piperazin-1-carbonyl-phenyl]}pyradizin-3-one | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
| WO-2007008144-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AS INHIBITORS OF FACTOR XA | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135441-A1 | New derivatives of 6-{4-[4-(1h-indole-2-sulphonyl)-piperazin-1-carbonyl-phenyl]}pyradizin-3-one | HTR7, TRPC7, HRH4 | F10 803/4885KDM4E 2216/4885POLB 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.